Skip to contentN
Northwest Biotherapeutics Inc
N
NWBONorthwest Biotherapeutics Inc Q1 2020 · 10-Q
Revenue$570.00K$570.00K+68.1% vs Q1 2019 Net Income$2.73M$2.73MN/M vs Q1 2019 EPS Diluted$0.00$0.00N/M vs Q1 2019 Operating Income-$7,733,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR
Margins · derivedOperating margin-1356.7%+934.2 pt vs Q1 2019
Net margin478.2%+6657.0 pt vs Q1 2019
ended Mar 31, 2020 · filed Jun 24, 2020 · 85 d after period end